EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have
How this was made
The 30-second read
Why it matters
The article provides the first pivotal readout and explicitly links the 67% stock crash to the missed primary endpoint, while also detailing secondary endpoint superiority (treatment burden) and safety/anatomic control. It also sets the next decision points: LUCIA top-line in Q4 2026 and potential NDA submission in 1H 2027 contingent on LUCIA.
Market read
Traders get a fresh, time-sensitive catalyst: a pivotal trial primary endpoint miss with quantified secondary benefits and a clear next catalyst timeline (LUCIA in Q4 2026).
What to watch
LUGANO is only the first of two pivotal studies; the market may be underweighting the probability-weighted impact of LUCIA results expected in Q4 2026 and the disclosed superiority on treatment burden.
Background
EyePoint is evaluating Duravyu (vorolanib intravitreal insert) in wet AMD with two identical phase III, Eylea-controlled studies (LUGANO and LUCIA) using six-month redosing.
Ticker impact
EyePoint’s Duravyu missed the phase III LUGANO primary endpoint versus Eylea, driving a reported 67% share plunge.
High probability of continued volatility and downside bias near-term, with potential mean-reversion attempts tied to LUCIA readout expectations.
The article attributes the 67% crash directly to the missed primary endpoint, while also disclosing specific secondary positives and an ad hoc analysis that could support a later regulatory path if LUCIA confirms.
Regeneron’s Eylea is the control arm in Duravyu’s phase III study, and the trial’s primary miss versus Eylea raises read-across risk for the competitor.
Likely limited direct impact versus EYPT, but some sentiment spillover is possible given the explicit head-to-head framing.
The article does not report any Eylea-specific negative result; it frames Eylea as the comparator and highlights an ad hoc analysis excluding an imbalance in vision loss.
Market effects
Reinforces that late-stage ophthalmology programs can reprice sharply on primary endpoint misses, even when secondary endpoints look supportive.
Primarily US-listed biotech sentiment; limited direct regional spillover beyond ophthalmology peers.
Wet AMD competitive dynamics may influence global investor perception of anti-VEGF delivery innovation and trial design robustness.
Counterpoint
The primary miss may be overstated if the imbalance-driven vision loss is the key driver, and the ad hoc exclusion suggests Duravyu can still clear non-inferiority hurdles.
Key entities
- companyEyePoint
Subject of the article; Duravyu phase III LUGANO results and subsequent stock plunge.
- drug_candidateDuravyu (vorolanib intravitreal insert)
Investigational therapy evaluated head-to-head versus Eylea in wet AMD.
- comparator_drugEylea (aflibercept)
On-label control arm and benchmark anti-VEGF therapy in the trial.
- companyRegeneron
Co-developer of Eylea; comparator in the pivotal study.
- companyBayer
Holds exclusive marketing rights for Eylea outside the US per the described agreement.
